Genoptix Joins Growing List of Companies Licensing TrovaGene's NPM1 for AML Testing | GenomeWeb

Trovagene announced last month that it has granted Novartis' diagnostics laboratory, Genoptix, a worldwide, non-exclusive license to incorporate the nucleophosmin protein marker into research and clinical testing services for acute myelogenous leukemia.

According to Trovagene, the terms of the agreement include both upfront fees and royalties. Detailed financial terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.